Winship Cancer Institute of Emory University | Strategic Alliance Partners

January 19, 2024

Jane L. Meisel, MD, discusses the impact of toxicities associated with endocrine therapy on quality of life as reported by patients with metastatic breast cancer.

January 16, 2024

Sagar Lonial, MD, FACP, details agents of interest outside CAR T-cell therapies in multiple myeloma, including elranatamab and talquetamab.

January 16, 2024

Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.

January 16, 2024

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

January 11, 2024

Jane L. Meisel, MD, shares data from a study on communication challenges between providers and patients with metastatic breast cancer regarding TRAEs.

December 29, 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

December 01, 2023

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

November 28, 2023

Mylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.

November 24, 2023

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

November 24, 2023

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

November 17, 2023

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

November 17, 2023

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

November 10, 2023

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

November 10, 2023

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.

November 09, 2023

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.

November 03, 2023

Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.

November 03, 2023

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

November 02, 2023

Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.

November 02, 2023

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

October 30, 2023

Madhav V. Dhodapkar, MBBS, discusses the advantages and disadvantages of bispecific antibodies and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma, as well as the potential role for the bispecific antibody linvoseltamab in this treatment paradigm.